A demonstration based on multi-omics transcriptome sequencing data revealed disulfidptosis heterogeneity within the tumor microenvironment of esophageal squamous cell carcinoma
Open Access
- 12 June 2023
- journal article
- research article
- Published by Springer Nature in Discover Oncology
- Vol. 14 (1) , 1-18
Abstract
Background: It is of great concern to identify prognostic signatures for the prediction and prediction of esophageal squamous cell carcinoma (ESCC), which is the lethal pathological type of malignancy. Method: Bulk RNA sequencing and scRNA-seq data were retrieved from GSE53624, GSE53622, and GSE188900. Disulfidptosis-related differentially expressed genes (DEGs) were identified between disulfidptosis-high score and disulfidptosis-low score groups. Functional annotation of DEGs were analyzed by Gene Ontology (GO). Consistent clustering and co-expression modules were analyzed, and then constructed a risk score model via multivariate Cox regression analysis. Immune infiltration and immunotherapy response analyses were conducted based on risk score. qRT-PCR, colony formation assay, and flow cytometry analysis were conducted in KYSE-150 and TE-1 cell lines. Results: Seven genes (CD96, CXCL13, IL2RG, LY96, TPK1, ACAP1, and SOX17) were selected as marker genes. CD96 and SOX17 are independent prognostic signatures for ESCC patients, with a significant correlation with infiltrated immune cells. ESCC patients had worse response to nivolumab in the high-risk group. Through cellular experiments, we found that CD96 expression was associated with apoptosis and cell cycle ESCC cells. Conclusion: In a word, the risk score based on disulfidptosis is associated with prognosis and the immune microenvironment, which may direct immunotherapy of ESCC. The key gene of risk score, namely CD96, plays a role in proliferation and apoptosis in ESCC. We offer an insight into the exploration of the genomic etiology of ESCC for its clinical management.Keywords
Funding Information
- the Innovation Team Project Foundation of Taizhou People’s Hospital (CXTDB201904)
- the Project Foundation of Taizhou School of Clinical Medicine, Nanjing Medical University (TZKY20220204, TZKY20220205)
This publication has 27 references indexed in Scilit:
- Multi-region sequencing unveils novel actionable targets and spatial heterogeneity in esophageal squamous cell carcinomaNature Communications, 2019
- Targeting CDC7 improves sensitivity to chemotherapy of esophageal squamous cell carcinomaOncoTargets and Therapy, 2018
- CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric CancerJournal of Clinical Oncology, 2018
- Cancer immunotherapy using checkpoint blockadeScience, 2018
- Prognostic value of an immunohistochemical signature in patients with esophageal squamous cell carcinoma undergoing radical esophagectomyMolecular Oncology, 2018
- Genomic and Epigenomic Aberrations in Esophageal Squamous Cell Carcinoma and Implications for PatientsGastroenterology, 2018
- MicroRNA-375 suppresses esophageal cancer cell growth and invasion by repressing metadherin expressionOncology Letters, 2017
- The tumor microenvironment in esophageal cancerOncogene, 2016
- Autoantibodies as Potential Biomarkers for the Early Detection of Esophageal Squamous Cell CarcinomaAmerican Journal of Gastroenterology, 2014
- Low SOX17 expression is a prognostic factor and drives transcriptional dysregulation and esophageal cancer progressionInternational Journal of Cancer, 2013